Well well well

Dr. Leonard Schleifer, Regeneron president and CEO denies the drug was made from stem cells. You believe anything CNN tells you huh?

Here MORON: https://www.usatoday.com/story/news/factcheck/2020/10/08/fact-check-trumps-antibody-therapy-not-made-fetal-stem-cells/5901542002/

Explain the difference between human fetus stem cells and human fetus-derived stem cells.

Go on.

What's the difference?

Typical leftist. There's the proof and you move the goal post. Your party is so divided, Genius.

The CEO said otherwise. But YOUR RIGHT...... Can't let your feelings get hurt little one.

Oh, poor duck, I know it's hard for you. But you'll have to do some thinking and then learn some science so you can explain how you know fetal-derived wasn't derived from a fetus.

Because I could say "no, this chocolate ice cream isn't bull feces. It's bull feces derived."

but it's still bull feces. With sprinkles.

Science is there in black and white. Literacy helps, son. Go ahead.

And you don't even have to rip the baby into little pieces---------- if Regeneron was made from fetal stem cells in the first place. So wrong whistlelock.

Regeneron calls its antibody cocktail REGN-COV2, a combination of two monoclonal antibodies, REGN10933 and REGN10987, that are designed to both treat people with COVID-19 and to prevent SARS-CoV-2 infection.

REGN10933 and REGN10987 were the two most potent, non-competing, and virus-neutralizing antibodies selected from thousands produced through Regeneron’s monoclonal antibody discovery platform VelocImmune®, part of the company’s VelociSuite™ technologies. Regeneron has said it has produced two distinct antibody cocktails, an initial cocktail and a backup.

VelocImmune® is our unique technology for producing fully human monoclonal antibodies. VelocImmune creates a multitude of optimized antibody drug candidates efficiently and directly from immunized mice. This approach overcomes the limitations of traditional platforms by rapidly creating fully human antibodies that tightly bind to therapeutic targets and avoid potential immune responses that may occur in patients receiving antibodies that contain nonhuman (typically mouse) components.

https://www.genengnews.com/insights/trumps-treatments-regenerons-antibodies-and-gileads-remdesivir-explained/

https://www.regeneron.com/technology